» Articles » PMID: 35358010

Knockdown of LncRNA HAGLROS Inhibits Metastasis and Promotes Apoptosis in Nephroblastoma Cells by Inhibition of Autophagy

Overview
Journal Bioengineered
Date 2022 Mar 31
PMID 35358010
Authors
Affiliations
Soon will be listed here.
Abstract

Nephroblastoma, or Wilms tumor, is a primary renal malignant tumor that easily occurs in children. Previous studies have revealed the regulatory functions of LncRNA in nephroblastoma. LncRNA HAGLROS functions as a tumor promotor in various cancers including hepatocellular carcinoma, ovarian cancer and colorectal cancer. In this study, the HAGLROS expression in nephroblastoma cells was assayed through qRT-PCR. Cell proliferation assessment employed CCK-8. Moreover, the migration and invasion of cells were examined separately through wound healing and transwell assay. Moreover, flow cytometric analysis and Western blot assay were applied to evaluate cell apoptosis. Rapamycin and 3-methyladenine were used to serve as autophagy activator or inhibitor, respectively. In addition, autophagy was identified by immunofluorescence staining and Western blot analysis. Experiment results showed that HAGLROS expressed highly in nephroblastoma cell lines. HAGLROS knockdown prevented cells from proliferating, and also showed suppressive impact on migration and invasion in HFWT cells. In addition, knockdown of HAGLROS showed a facilitative effect on apoptosis and an inhibitory effect on autophagy. Stimulation of autophagy alleviated HAGLROS silencing-induced apoptosis, while inhibition of autophagy reversed the effect in nephroblastoma cells. In summary, our results revealed that HAGLROS executed an oncogenic role in the progress of nephroblastoma, offering a new perspective on the strategy for nephroblastoma therapy.

Citing Articles

LncRNA HAGLROS promotes breast cancer evolution through miR-135b-3p/COL10A1 axis and exosome-mediated macrophage M2 polarization.

Meng Z, Zhang R, Wu X, Piao Z, Zhang M, Jin T Cell Death Dis. 2024; 15(8):633.

PMID: 39198393 PMC: 11358487. DOI: 10.1038/s41419-024-07020-x.


Construction and verification of a novel circadian clock related long non-coding RNA model and prediction of treatment for survival prognosis in patients with hepatocellular carcinoma.

Zhang Z, Gao W, Tan X, Deng T, Zhou W, Jian H BMC Cancer. 2023; 23(1):57.

PMID: 36647032 PMC: 9843932. DOI: 10.1186/s12885-023-10508-y.

References
1.
Tang F, Lu Z, Wang J, Li Z, Wu W, Duan H . Competitive endogenous RNA (ceRNA) regulation network of lncRNAs, miRNAs, and mRNAs in Wilms tumour. BMC Med Genomics. 2019; 12(1):194. PMC: 6915924. DOI: 10.1186/s12920-019-0644-y. View

2.
Zhao X, Han B, Zhao J, Tao N, Dong C . MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1. Eur Rev Med Pharmacol Sci. 2019; 23(3):1030-1037. DOI: 10.26355/eurrev_201902_16990. View

3.
Watson J, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A . miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS One. 2013; 8(1):e53417. PMC: 3538586. DOI: 10.1371/journal.pone.0053417. View

4.
Sakai O, Sakurai M, Sakai H, Kubo M, Hiraoka H, Baba K . Molecular cloning of canine Wilms' tumor 1 for immunohistochemical analysis in canine tissues. J Vet Med Sci. 2017; 79(7):1272-1277. PMC: 5559376. DOI: 10.1292/jvms.17-0229. View

5.
Zhao M, Xin X, Zhang J, Dai W, Lv T, Song Y . LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling. Cancer Med. 2019; 9(3):1196-1208. PMC: 6997056. DOI: 10.1002/cam4.2776. View